AbbVie (NYSE:ABBV) Price Target Cut to $240.00 by Analysts at Cantor Fitzgerald

AbbVie (NYSE:ABBV) had its price objective decreased by Cantor Fitzgerald from $250.00 to $240.00 in a report issued on Wednesday morning,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the stock.

A number of other analysts have also issued reports on ABBV. Berenberg Bank set a $275.00 target price on AbbVie in a report on Tuesday, January 20th. UBS Group lowered their target price on AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a report on Thursday, February 5th. Evercore reduced their price target on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and upped their price target for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Finally, BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average target price of $252.65.

AbbVie Trading Up 2.6%

Shares of ABBV stock opened at $211.74 on Wednesday. The stock has a market capitalization of $374.40 billion, a price-to-earnings ratio of 89.72, a price-to-earnings-growth ratio of 0.73 and a beta of 0.38. AbbVie has a 12-month low of $164.39 and a 12-month high of $244.81. The stock’s 50-day moving average price is $220.80 and its 200-day moving average price is $224.19.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the business posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts predict that AbbVie will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s payout ratio is presently 293.22%.

Insider Activity at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On AbbVie

Institutional investors have recently modified their holdings of the business. Chelsea Counsel Co. acquired a new position in shares of AbbVie during the third quarter worth $26,000. Litman Gregory Wealth Management LLC acquired a new position in shares of AbbVie during the fourth quarter worth $28,000. Imprint Wealth LLC grew its stake in shares of AbbVie by 56.3% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares in the last quarter. Westend Capital Management LLC acquired a new position in shares of AbbVie during the fourth quarter worth $29,000. Finally, IFC & Insurance Marketing Inc. acquired a new position in shares of AbbVie during the fourth quarter worth $31,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie filed a lawsuit seeking clearer, narrower guidance on which patients qualify for a federal drug discount program — a step that could limit discount exposure and protect revenue/margins if the court or settlement tightens eligibility. AbbVie files lawsuit to address ‘outdated’ drug discount eligibility program
• Positive Sentiment: New dermatology data showcased at the AAD meeting (Skyrizi and Rinvoq long‑term outcomes, safety and expanded labels) support AbbVie’s immunology growth thesis and help de‑risk revenue concentration away from Humira. Can AbbVie’s (ABBV) New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story?
• Positive Sentiment: Analyst support and dividend/cash‑flow strength: recent analyst notes (including high price targets from JPMorgan and an overweight stance from Cantor Fitzgerald despite a modest PT trim) plus strong free cash flow and a reliable dividend underpin investor confidence. AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns Cantor Fitzgerald lowers price target to $240, remains Overweight
• Neutral Sentiment: Broader health-care sector strength lifted stocks broadly today, providing a tailwind to ABBV alongside company‑specific news. Sector Update: Health Care Stocks Advance in Afternoon Trading
• Neutral Sentiment: Market commentary and trending coverage (Zacks, Seeking Alpha) are spotlighting AbbVie’s pipeline and dividend, keeping the name on investor radars but not adding new hard catalysts. AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: AbbVie added Humira to the TrumpRx program at a steep (reported ~86%) discount for broader access — a move that could pressure Humira residual revenues and overall pricing power in the U.S. over time. Humira’s TrumpRx Discount Raises New Questions For AbbVie Valuation
• Negative Sentiment: Valuation and guidance risks remain: some analysts and commentators flag that recent volatility, competitive pressures and any guidance softness could limit upside despite strong drug growth — a caution that can weigh on the stock if sentiment flips. Why The AbbVie (ABBV) Story Is Shifting As Immunology Hopes Meet Valuation Doubts

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.